Efficacy and safety of dutasteride compared with finasteride in treating males with benign prostatic hyperplasia: A meta‑analysis of randomized controlled trials

Zhou,Zhongbao; Cui,Yuanshan; Wu,Jitao; Jin,Hairong

doi:10.3892/etm.2020.8851

Efficacy and safety of dutasteride compared with finasteride in treating males with benign prostatic hyperplasia: A meta‑analysis of randomized controlled trials

Authors:
- Zhongbao Zhou
- Yuanshan Cui
- Jitao Wu
- Hairong Jin
View Affiliations

Affiliations: School of Clinical Medicine, Binzhou Medical University, Yantai, Shandong 264000, P.R. China, Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P.R. China
Published online on: June 10, 2020 https://doi.org/10.3892/etm.2020.8851
Pages: 1566-1574
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study was an updated meta‑analysis that aimed to confirm the efficacy and safety of dutasteride (0.5 mg) and finasteride (5 mg) in treating males with benign prostatic hyperplasia (BPH) over a treatment period of at least 6 months. Randomized controlled trials were retrieved using the MEDLINE, EMBASE and the Cochrane controlled trials register databases. The references of the associated articles were also searched. A systematic review was performed by using the preferred reporting items for systematic reviews and meta‑analyses. The data were analyzed with RevMan v5.3.0. A total of six articles including 2,041 participants were studied. The analysis demonstrated a significantly greater decrease in international prostate symptom score [IPSS; mean difference (MD), ‑0.86; 95% CI, ‑1.62 to ‑0.11; P=0.02] and prostate‑specific antigen (PSA; MD, ‑0.13; 95% CI, ‑0.26 to ‑0.01; P=0.03) in the dutasteride group compared with that in the finasteride group, whereas no significant differences were observed in prostate volume (PV; P=0.64), maximum urine flow rate (Qmax; P=0.29) and post‑void residual volume (PVRV; P=0.14). With regard to safety assessment, including any adverse event (P=0.66), decreased libido (P=0.39) and impotence (P=0.17), there was no significant difference between dutasteride and finasteride. In conclusion, in patients with BPH, dutasteride produced a greater decrease in IPSS and PSA compared with finasteride, whereas no significant differences were identified in PV, Qmax and PVRV. The two drugs appeared to have similar rates of adverse effects, particularly with regard to sexual dysfunction.

View Figures

View References

1	Guess HA, Arrighi HM, Metter EJ and Fozard JL: Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. Prostate. 17:241–246. 1990.PubMed/NCBI View Article : Google Scholar
2	Lepor H, Williford W, Barry M, Haakenson C and Jones K: The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. J Urol. 160:1358–1367. 1998.PubMed/NCBI
3	AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol. 170:530–547. 2003.PubMed/NCBI View Article : Google Scholar
4	Anderson JB, Roehrborn CG, Schalken JA and Emberton M: The progression of benign prostatic hyperplasia: Examining the evidence and determining the risk. Eur Urol. 39:390–399. 2001.PubMed/NCBI View Article : Google Scholar
5	Roehrborn CG, McConnell JD, Lieber M, Kaplan S, Geller J, Malek GH, Castellanos R, Coffield S, Saltzman B, Resnick M, et al: Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group Urology. 53:473–480. 1999.PubMed/NCBI View Article : Google Scholar
6	Deslypere JP, Young M, Wilson JD and McPhaul MJ: Testosteronem and 5 alpha-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene. Mol Cell Endocrinol. 88:15–22. 1992.PubMed/NCBI View Article : Google Scholar
7	Welén K and Damber JE: Prostate diseases-role of sex steroids and their inhibitors. Best Pract Res Clin Endocrinol Metab. 25:355–367. 2011.PubMed/NCBI View Article : Google Scholar
8	Griffiths K, Eaton CL, Harper ME, Peeling B and Davies P: Steroid hormones and the pathogenesis of benign prostatic hyperplasia. Eur Urol. 20 (Suppl 1):S68–S77. 1991.PubMed/NCBI View Article : Google Scholar
9	Naslund M, Regan TS, Ong C and Hogue SL: 5-Alpha reductase inhibitors in men with an enlarged prostate: An evaluation of outcomes and therapeutic alternatives. Am J Manag Care. 14 (5 Suppl 2):S148–S153. 2008.PubMed/NCBI
10	McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, Albertsen P, Roehrborn CG, Nickel JC, Wang DZ, et al: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med. 338:557–563. 1998.PubMed/NCBI View Article : Google Scholar
11	Roehrborn CG, Boyle P, Nickel JC, Hoefner K and Andriole G: ARIA3001 ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 60:434–441. 2002.PubMed/NCBI View Article : Google Scholar
12	Yin T, Qiao Z, Li Y, Li D, Jiang M, An C, Wang F, Zuo M, Hu K and Li Q: Comparisons of the efficacy and safety of finasteride and dutasteride for benign prostatic hyperplasia: A network meta-analysis. Am J Ther. 24:e517–e523. 2017.PubMed/NCBI View Article : Google Scholar
13	Jun JEJ, Kinkade A, Tung ACH and Tejani AM: 5α-reductase inhibitors for treatment of benign prostatic hyperplasia: A systematic review and meta-analysis. Can J Hosp Pharm. 70:113–119. 2017.PubMed/NCBI View Article : Google Scholar
14	Moher D, Liberati A, Tetzlaff J and Altman DG: PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med. 151:264–269. 2009.PubMed/NCBI View Article : Google Scholar
15	Jadad AR: Randomised controlled trials: A user's guide. BMJ Publishing Group, London, 1998.
16	Higgins JP and Green S (eds): Cochrane handbook for systematic reviews of interventions. Version 5.1.0. The Cochrane Collaboration, 2011. http://www.cochrane-handbook.orgsimplewww.cochrane-handbook.org. Updated March 2011.
17	DerSimonian R and Laird N: Meta-analysis in clinical trials. Control Clin Trials. 7:177–188. 1986.PubMed/NCBI View Article : Google Scholar
18	Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB and Hobbs S: Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab. 89:2179–2184. 2004.PubMed/NCBI View Article : Google Scholar
19	Mohanty NK, Singh UP, Sharma NK, Arora RP and Amitabh V: A comparative study of fixed dose of tamsulosin with finasteride vs tamsulosin with dutasteride in the management of benign prostatic hyperplasia. Indian J Urol. 22:130–134. 2006.
20	Jeong YB, Kwon KS, Kim SD and Kim HJ: Effect of discontinuation of 5alpha-reductase inhibitors on prostate volume and symptoms in men with BPH: A prospective study. Urology. 73:802–806. 2009.PubMed/NCBI View Article : Google Scholar
21	Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH and Rittmaster RS: Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: The Enlarged Prostate International Comparator Study (EPICS). BJU Int. 108:388–394. 2011.PubMed/NCBI View Article : Google Scholar
22	Li Y and Wang J: Clinical efficacy and safety analysis of dutasteride in treatment of benign prostatic hyperplasia. Chinese J Androl. 27:49–55. 2013.
23	Qian X, Yu G, Qian Y, Xu D, Liu H, Kong X, Zhu Y, Wang Z, Zheng J and Qi J: Efficacy of 5α-reductase inhibitors for patients with large benign prostatic hyperplasia (>80 ml) after transurethral resection of the prostate. Aging Male. 18:238–243. 2015.PubMed/NCBI View Article : Google Scholar
24	Girman CJ: Population-based studies of the epidemiology of benign prostatic hyperplasia. Br J Urol. 82 (Suppl 1):S34–S43. 1998.PubMed/NCBI View Article : Google Scholar
25	Emberton M, Andriole GL, de la Rosette J, Djavan B, Hoefner K, Vela Navarrete R, Nordling J, Roehrborn C, Schulman C, Teillac P, et al: Benign prostatic hyperplasia: A progressive disease of aging men. Urology. 61:267–273. 2003.PubMed/NCBI View Article : Google Scholar
26	Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA and Lieber MM: Natural history of prostatism: Risk factors for acute urinary retention. J Urol. 158:481–487. 1997.PubMed/NCBI View Article : Google Scholar
27	Corona G, Vignozzi L, Rastrelli G, Lotti F, Cipriani S and Maggi M: Benign prostatic hyperplasia: A new metabolic disease of the aging male and its correlation with sexual dysfunctions. Int J Endocrinol. 2014(329456)2014.PubMed/NCBI View Article : Google Scholar
28	O'Leary MP, Roehrborn CG and Black L: Dutasteride significantly improves quality of life measures in patients with enlarged prostate. Prostate Cancer Prostatic Dis. 11:129–133. 2008.PubMed/NCBI View Article : Google Scholar
29	Corona G, Tirabassi G, Santi D, Maseroli E, Gacci M, Dicuio M, Sforza A, Mannucci E and Maggi M: Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: A comprehensive review and meta-analysis. Andrology. 5:671–678. 2017.PubMed/NCBI View Article : Google Scholar
30	Shibata Y, Arai S, Miyazawa Y, Shuto T, Nomura M, Sekine Y, Koike H, Matsui H, Ito K and Suzuki K: Effects of steroidal antiandrogen or 5-alpha-reductase inhibitor on prostate tissue hormone content. Prostate. 77:672–680. 2017.PubMed/NCBI View Article : Google Scholar
31	Evans HC and Goa KL: Dutasteride. Drugs Aging. 20:905–918. 2003.PubMed/NCBI View Article : Google Scholar
32	Guess HA, Gromley GJ, Stoner E and Oesterling JE: The effect of finasteride on prostate specific antigen: Review of available data. J Urol. 155:3–9. 1996.PubMed/NCBI
33	Schröder FH: Review of diagnostic markers for prostate cancer. Recent Results Cancer Res. 181:173–182. 2009.PubMed/NCBI View Article : Google Scholar
34	Morgia G, Urzì D and Russo GI: 5ARI and PSA: Evidences. Urologia. 81 (Suppl 24):S4–S11. 2014.PubMed/NCBI View Article : Google Scholar : (In Italian).
35	Andriole GL, Bostwick D, Brawley OW, Gomella L, Marberger M, Montorsi F, Pettaway C, Tammela TL, Teloken C, Tindall D, et al: The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: Results from the REDUCE study. J Urol. 185:126–131. 2011.PubMed/NCBI View Article : Google Scholar
36	Traish A, Haider KS, Doros G and Haider A: Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction. Horm Mol Biol Clin Investig 30, 2017.